# Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

> **NCT03226067** · PHASE2 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 111 (actual)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** GKT137831
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03226067
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-04-11
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2022-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226067, "Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03226067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*